Neoadjuvant Chemotherapy Clinical Trial
Official title:
Sequential Use of Nab-paclitaxel Plus Gemcitabine and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer: A Randomized Control Study
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen. Studies have shown that sequential chemotherapeutic regimen can effectively delay the drug resistance and improve the effect of chemotherapy. Here investigators intend to assess the effect of sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox as neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Investigators chose resectable pancreatic adenocarcinoma patients. The planned treatment was given to the participants after randomization. Tumor size, recurrence-free survival, overall survival, drugs related side effects and other endpoints events were recorded and analyzed, to assess the sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox could or couldn't benefit the prognosis of resectable pancreatic adenocarcinoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Active, not recruiting |
NCT03719833 -
Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
|
||
Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
Not yet recruiting |
NCT04384601 -
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04576143 -
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
Recruiting |
NCT03493880 -
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
|
||
Completed |
NCT06149884 -
Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
|
||
Recruiting |
NCT03715686 -
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes
|
N/A | |
Recruiting |
NCT05522985 -
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT03349177 -
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
|
Phase 2/Phase 3 | |
Terminated |
NCT03585062 -
Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT06120309 -
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
|
||
Recruiting |
NCT04004559 -
MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
|
||
Recruiting |
NCT04047693 -
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT06220214 -
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT05910710 -
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
|
||
Suspended |
NCT05503108 -
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05367206 -
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
|
Phase 3 | |
Completed |
NCT06151379 -
Muscle Parameters and Pathological Response in Breast Cancer Patients
|